Protocol Ledger

NCT03510897 · Phase III · TERMINATED

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

Interventional Phase III clinical trial protocol NCT03510897 sponsored by Quark Pharmaceuticals in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-06-29 Enrollment: 1,043 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03510897
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,043 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03510897
Protocol FieldVerified Registry Value
NCT IdentifierNCT03510897
Consolidated Lead SponsorQuark Pharmaceuticals
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment1,043 participants (ACTUAL)
Registered Start Date2018-06-29
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI